Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
ImmuCell Corp Market Cap
From what 0 stock analysts predict, the share price for ImmuCell Corp (ICCC) might decrease by 100% in the next year. This is based on a 12-month average estimation for ICCC. Price targets go from $ to $. The majority of stock analysts believe ICCC is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
ICCC is a stock in Health Care which has been forecasted to be worth $ as an average. On the higher end, the forecast price is $ USD by from and on the lower end ICCC is forecasted to be $ by from .
These are the latest 20 analyst ratings of ICCC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Nathan Weinstein Aegis Capital | Buy | $14 | Initiates | Jul 13, 2020 |
When did it IPO
1987
Staff Count
75
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Michael F. Brigham
Market Cap
$28.4M
In 2023, ICCC generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ICCC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 05 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - PORTLAND, Maine, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:u00a0ICCC) (u201cImmuCellu201d or the u201cCompanyu201d), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, todayu00a0announced preliminary, unaudited sales results for the third quarter of 2023, which ended September 30, 2023.
Tue, 29 Aug 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - PORTLAND, Maine, Aug. 29, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:u00a0ICCC) (u201cImmuCellu201d or the u201cCompanyu201d), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced todayu00a0that it recently submitted the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain u00ae to the FDA.
Fri, 11 Aug 2023
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - ImmuCell Corporation (NASDAQ:ICCC ) Q2 2023 Earnings Conference Call August 11, 2023 9:00 AM ET Company Participants Joe Dorame - Lytham Partners, IR Michael Brigham - President and Chief Executive Officer Conference Call Participants Operator Good day, and welcome to the ImmuCell Corporation Reports Second Quarter Fiscal Year 2023 Financial Results Conference Call. All participants will be in a listen-only mode.
Thu, 10 Aug 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - PORTLAND, Maine, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:u00a0ICCC) (u201cImmuCellu201d or the u201cCompanyu201d), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, todayu00a0announced its unaudited financial results for the quarter ended June 30, 2023.
Mon, 07 Aug 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - PORTLAND, Maine, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:u00a0ICCC) (u201cImmuCellu201d or the u201cCompanyu201d), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2023 after the market closes on Thursday, August 10, 2023. The Company has scheduled a conference call the next morning, Friday, August 11, 2023, at 9:00 AM ET to review its second quarter financial results.
Tue, 11 Jul 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - PORTLAND, Maine, July 11, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq:u00a0ICCC) (u201cImmuCellu201d or the u201cCompanyu201d), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, todayu00a0announced preliminary, unaudited sales results for the second quarter of 2023, which ended June 30, 2023.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
